

RESEARCH ARTICLE**A STUDY OF ADVERSE DRUG REACTIONS
IN A TERTIARY CARE HOSPITAL OF PUNE**

Dr. Steffi Jerry Mammen
Clinical Pharmacist,
Inamdar Multispecialty Hospital, Pune, India

Correspondence

Dr. Joel Thomas, Pharm D
Sect no. 103/2/1, Lilly villa,
Kinara Colony-B, Vijaynagar,
Pimpri, Kalewadi, Pune,
Email Id:
steffi.thomas@ymail.com

Keywords

Pharmacovigilance,
chemotherapy, adverse drug
reactions, oncology Tertiary
Care Hospital.

Received

12/07/2018

Reviewed

18/07/2018

Accepted

20/07/2018

ABSTRACT

To study the adverse drug reactions reported from wards and critical units in a tertiary care hospital of Pune. The adverse drug reactions were analyzed by Naranjo's algorithm scale and Hart wig severity assessment scale and the outcomes were studied. This observational and cross-sectional study was conducted for 6 months from November 2016-May 2017 in an inpatient setting of a tertiary care hospital of Pune. Patients of all age groups and either sex were included in this study. The adverse drug reactions were checked for their causality and severity by performing the Naranjo's algorithm scale and Hart wig's scale respectively. Data analysis was done by descriptive statistics. Total 50 adverse drug reactions were reported from wards and critical units. 21-30 years age group was reported to have more adverse drug reactions. The most common organ affected is the Skin 32 (71.11%), followed by Respiratory system 3 (6.66%) and nervous system 3 (6.66%). Vancomycin 5 (20%) was the drug having majority of the ADR's. The commonly reported ADR in this study was rash and itching 29 (64.44%). According to Naranjo's algorithm scale, 23 (51.11%) suspected ADR's were probable, 17 (37.77%) ADR's were possible and 5(11.11%) were definite. As per Hart wig's severity assessment scale, majority of the ADR's were mild 21 (46.66%), followed by moderate 20 (44.44%) and severe 4 (8.88%). The outcome of the ADR's was all recovered 38 (84.44%) during the study period. Study was conducted only in wards and critical units not in all departments of the hospital.

INTRODUCTION

Drugs have primarily used for diagnosis, prevention, treatment of various diseases and to alleviate pain. But it is sometimes observed, that these drugs have been proved fatal. This could be due to variable person-to-person response towards a drug. Even at therapeutic doses, people develop adverse effects. World health organization (WHO) defines an adverse drug reaction (ADR),” As a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function” According to epidemiological studies, ADR’s account to 5% of hospital admissions and occur in 10-20% of hospitalized patients. It is the 7th leading cause of death. ADR’s are a leading cause of morbidity and mortality in many countries. It is a great concern for public, medical professionals, pharmaceutical industry and regulatory authorities.

India is a country which has supported the WHO program for global monitoring of ADR’s that wholly depends on spontaneous reporting. Spontaneous reporting is a very cost effective and affordable system which can identify rare adverse reactions and generate early signals for new drugs.

Because of this reporting system, many drugs are recalled from the market due to safety concerns. The concept of ADR reporting in India is very primitive and the reporting done is also rare. If proper awareness among health care professionals is provided, it can contribute to drug safety and better patient care. Hence, this study was conducted to identify, analyze the various ADR’s in a clinical setting and study their outcomes.

OBJECTIVE

1. To study the adverse drug reactions reported from wards and critical units in a tertiary care hospital of Pune.
2. To analyze the adverse drug reactions by Naranjo’s algorithm scale and Hart wig severity assessment scale and determine the outcome.

METHODOLOGY

This observational and cross-sectional study was conducted for 6months from November 2016-May 2017 in an inpatient setting of a tertiary care hospital in Pune. The data was captured only in wards and critical units. Patients of all age groups and either sex were included in this study. The Adverse drug reaction form filled by Resident Medical Officer was considered. The

documentation of the adverse drug reaction form was maintained by the clinical pharmacist for evaluation and further study. The adverse drug reactions were checked for their causality and severity by performing the Naranjo's algorithm scale and Hart wig's scale respectively. The outcomes were studied. Data analysis was done by descriptive statistics.

Exclusion criteria: Known allergies or previous history given by patients regarding drug allergies are excluded from this study. OPD patients are also excluded. The use of alternative system of medicines such as Ayurveda, Homeopathy, Unani. As well as over dosage, excess consumption, was excluded. Patients who are mentally retarded, drug addicted, suicidal tendencies or consumption of a drug in the influence of alcohol was also excluded.

Statistics: Description statistics were used for data analysis.

RESULTS AND DISCUSSION

In this study, 50 patients were reported to experience an ADR during the study. 5 ADR cases were discarded as more than one suspected drug was documented. Out of 45 patients, 24 (53.33%) were females and 21 (46.66%) were males. The median age of

the patients was 25. The patient who documented an ADR was as young as 9 months and the oldest was of 84 years. Majority of the patients experiencing an ADR were belonging in the age group of 21-30 years (Table 1). It was also found that, the most common route of administration for suspected drugs was Intravenous 30 (66.66%), followed by oral 5 (11.11%) and then topical 4 (8.88%) (Table-2). As shown in the (Table-3) the most common organ affected is the Skin 32 (71.11%), followed by Respiratory system 3 (6.66%) and nervous system 3 (6.66%).

The drug class which encountered commonly with ADR's was Antimicrobials 22 (48.88%), followed by NSAID's 5 (11.11%) (Table-4). Vancomycin 5 (20%) was the drug having majority of the ADR's. The commonly reported ADR in this study was rash and itching 29 (64.44%). According to Naranjo's algorithm scale, 23 (51.11%) suspected ADR's were probable, 17 (37.77%) ADR's were possible and 5 (11.11%) were definite (Table-5, 6). As per Hart wig's severity assessment scale, majority of the ADR's were mild 21 (46.66%), followed by moderate 20 (44.44%) and severe 4 (8.88%) (Table 7, 8). The outcome of the ADR's was all

recovered 38 (84.44%) during the study period (Table-9).

CONCLUSION

Adverse drug reactions is a drug related problem and if proper monitoring is done, it can contribute to drug safety. Rational use of antibiotics can help reduce the occurrence of ADR's to a great extent. In this study, 25 suspected drugs were reported to induce ADRs. After an ADR, the drug was withdrawn and recalling was not performed in any patient. Majority of ADRs experienced was, more in females than in males. This study mainly focused on ADRs admitted as Inpatients in wards and critical units. The most common route of administration was intravenous. ADR's were more in Antimicrobials, followed by NSAID's, and Vancomycin was the drug having majority of the ADR's. The commonly reported ADR in this study was rash and itching. Majority of the ADR's in this study were mild in nature and mostly all recovered during the study period. There is a need for more of spontaneous reporting by all health care professionals working in various departments in a tertiary care hospital. After an ADR occurrence, patient counseling is mandatory so that the patient is aware about it and can avoid further

exposure to the drug in future. This can also help in reducing the length of stay of patients and also can be cost effective. The active involvement of clinical pharmacist to capture ADR's and awareness given via training to other health care professionals can help change the scenario in under-reported hospitals.

REFERENCES

1. M. Shamna, C. Dilip, M. Ajmal, P. Linu Mohan, C. Shinu, C.P. Jafer, Yahiya Mohammed, 2014. A prospective study on adverse drug reactions of antibiotics in a tertiary care hospital. *Saudi Pharmaceutical Journal* 22, 303–308.
2. Hui li, Xiao Jing Guo, Xiao Fei Ye, Hong Jiang, Wen Min Du, Jin Fang Xu, Xin Ji Zhang, Jia He, 2014. Adverse drug reactions of spontaneous reports in Shanghai pediatric population. *PLoS ONE* 9(2).
3. Vikas Dhikav, Sindhu Singh, KS Anand, 2004. Adverse drug monitoring in India. *Clinical Pharmacology, JIACM* 5(1) 27-33.
4. Prakash H. Bhabhor, Tejas Kamleshbahi Patel, Roshni Vahora, Parvati B. Patel, Nimisha Desai, 2014. Adverse drug reactions in a tertiary care teaching hospital in India: analysis of spontaneously reported cases. *Inte. Jou. of Basic & clin. P'cology*, V 3, I 6, 1078-1086.

5. Ratan J. Lihite , Mangala Lahkar, Sukirti Das, Debeeka Hazarika, Murali Kotni, Mudasir Maqbool, Swapna Phukan , 2017. A study on adverse drug reactions in a tertiary care hospital of north-east India. Alexandria Journal of Medicine 53, 151–156.
6. Lateef M. Khan, Sameer E. Al-Harthi, Omar I. Saadah 2013. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharmaceutical Journal 21, 261–266.
7. Tilaye Shibbiru, Fanos Tadesse, 2016. Adverse Drug Reactions: An Overview. Journal of Medicine, Physiology and Biophysics, Vol.23, 2016, 1-9.
8. Asawari Raut, Arundati Diwan, Chitan Patel, Palak Patel, Atmaram Pawar, 2011. Incidence, Severity and financial burden associated with adverse drug reactions in medicine inpatients. Asian Journal of Pharmaceutical and Clinical Research, Vol 4, Supp 2.
9. Padmaja Uday Kumar, Prabha Adhikari, Pratibha Periera, 2009. A Prospective Analysis of Adverse Drug Reactions in a South Indian Hospital. Online Journal of Health and Allied Sciences, Volume 8, Issue 3:1-6.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther; 80:289–95.
11. Hartwig SC, Siegel J, Schneider PJ, 1992. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm, 49:2229-32.
12. Jacoline C. Bouvy, Marie L. De Bruin, Marc A. Koopmanschap, 2015. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf 38:437–453.
13. R. Arulmani, S.D. Rajendran & B. Suresh, 2011. Adverse drug reaction monitoring in a secondary care hospital in South India. British Journal of Clinical Pharmacology (2), 210-216.
14. Joel Thomas, Joshin Sara Cherian, Feba Susan Varghese, Shelina Hephzibah S, Vijay MC, Lijo James, 2018. Clinical Adverse Drug Reaction of Anti-Neoplastic Agents. JMPAS, jour. Of med. Phar and allied sci. V 7 - I 2, 755, 2018, 1000-1007.
15. Safety of medicines, a guide to detecting and reporting adverse drug reactions, WHO, Geneva 2002.

EXPERIMENTAL RESULT AND TABLE

Sr.No	Males	Females	Age Range	Total no of patients (%)
	4	1	≤1-10	5 (11.11%)
2	5	1	11-20	6 (13.33%)
3	2	11	21-30	13 (28.88%)
4	2	3	31-40	5 (11.11%)
5	0	2	41-50	2 (4.44%)
6	4	2	51-60	6 (13.33%)
7	4	4	≤61	8 (17.77%)
Total	21	24		45

Table-1

Route of Drug administration		
Sr.No	Route	Total (%)
1	Oral	5 (11.11%)
2	Intravenous	30 (66.66%)
3	Subcutaneous	3 (6.66%)
4	Intra-vaginal	2 (4.44%)
5	Topical	4 (8.88%)
6	Intra-muscular	1(2.22%)
Total		45

Table-2

Organ system affected by ADR		
Sr.No	Organ system	No. of ADR (%)
1	Skin	32 (71.11%)
2	Respiratory	3 (6.66%)
3	Musculoskeletal	1(2.22%)
4	Nervous	3(2.22%)
5	Digestive	1(2.22%)
6	Genitourinary	1(2.22%)
7	Other	4 (8.88%)
8	Total	45

Table-3

Drug Class		
Sr.No.	Category of drug	No.of ADR's (%)
1.	Antimicrobials	22 (48.88%)
2.	NSAID's	5 (11.11%)
3.	Proton pump inhibitors	4 (8.88%)
4.	Vitamins/minerals	4 (8.88%)
5.	Other	4 (8.88%)
6.	Cardiovasculars	3(6.66%)
7.	Anti-emetic	2(4.44%)
8.	Steroid	1(2.22%)

Table-4

Naranjo's algorithm scale for causality assessment of ADR

	Question	Yes	No	Don't know
1.	Are there previous conclusive reports on this reaction	+1	0	0
2.	Did the adverse event appear after the suspected drug was administered?	+2	-1	0
3.	Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?	+1	0	0
4.	Did the adverse event reappear when the drug was re-administered?	+2	-1	0
5.	Are there alternative causes (other than drug) that could on their own have caused the reaction?	-1	+2	0
6.	Did the reaction re-appear when a placebo was given?	-1	+1	0
7.	Was the drug detected in blood (or other fluids) in concentration known to be toxic?	+1	0	0
8.	Was the reaction more severe when the dose was increased or less severe when the dose was decreased?	+1	0	0
9.	Did the patient have a similar reaction to the same or similar drugs in any previous exposure?	+1	0	0
10.	Was the adverse event confirmed by any objective evidence?	+1	0	0

Table-5

Naranjo's Causality Assessment score.		My score (%)
Definite	>9	5 (11.11%)
Probable	5-8	23 (51.11%)
Possible	1-4	17 (37.77%)
Doubtful	0	0

Table-6

Hartwig's severity assessment scale
Mild reactions which were self-limiting and able to resolve over time without treatment and did not contribute to prolongation of length of stay.
Moderate ADR's were defined as those that required therapeutic intervention and hospitalization prolonged by 1 day but resolved in <24hrs or change in drug therapy or specific treatment to prevent a further outcome
Severe ADR's were those that were life threatening, producing disability and those that prolonged hospital stay or led to hospitalization, required intensive medical care or led to the death of the patient.

Table-7

My score	
Mild	21(46.66%)
Moderate	20 (44.44%)
Severe	4 (8.88%)

Table-8

Outcome:

Recovered	38 (84.44%)
Continuing	3 (6.66%)
Recovering	4 (8.88%)
Unknown	0
Fatal	0

Table-9

Suspected drugs with ADR

Sr.No.	Suspected drug	No. of ADR	Description of an ADR
1	Vancomycin	5	Rash and itching (5)
2.	Ceftriazone	3	Urticaria, Rash and itching (2)
3.	Ranitidine	3	Palpitation, Rash and itching (2)
4.	Povidone Iodine	3	Severe burning in vagina Rash and itching (1), Vomiting
5.	Diclofenac	3	Rash and itching (1), Breathlessness Giddiness
6.	Ferric Carboxymaltose	2	Rash and itching (2)
7.	Piperacillin+Tazobactam	2	Rash and itching (2)
8.	Polymixin-B	2	Dizziness Rash and itching (1)
9.	Amiodarone	2	Phlebitis , Rash and itching (1)
10.	Tramadol	2	Rash and itching (1), Restlessness,
11.	Amphotericin B	1	Rash and itching (1)
12.	Cefotaxim	2	Urticaria , Rash and itching (1)
13.	Cefixime	1	Rash and itching (1)
14.	Orofer FCM MVI (Multivitamin)	2	Tingling sensation at injection site,Rash and itching (1)
15.	Colistimethate Sodium	1	Numbness over face and upper lips, breathing difficulty
16.	Ciprofloxacin	2	Rash and itching (1), Swelling of lips
17.	Hydrocortisone	1	Rash and itching (1)
18.	Drotaverine	1	Rash and itching (1)
19.	Omeprazole	1	Reddish discoloration on injection site, rash and itching (1)
20.	Levofloxacin	2	Tachycardia, Tachypnoea(1) Breathlessness (1)
21.	Antithymocyte immunoglobulins	1	Rash and itching (1)
22.	Terlipressin acetate	1	Skin necrosis
23	Ondansetron	2	Rash and itching (1) Rash and no itching (1)

Table 10